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Aims Pathological arterial remodelling including neointimal hyperplasia and atherosclerosis is the main underlying cause
for occluding arterial diseases. Cezanne is a novel deubiquitinating enzyme, functioning as a NF-rB negative regula-
tor, and plays a key role in renal inflammatory response and kidney injury induced by ischaemia. Here we





Cezanne expression levels were consistently induced by various atherogenic stimuli in VSMCs, and in remodelled
arteries upon injury. Functionally, VSMCs over-expressing wild-type Cezanne, but not the mutated catalytically-
inactive Cezanne (C209S), had an increased proliferative ability and mobility, while the opposite was observed in
VSMCs with Cezanne knockdown. Surprisingly, we observed no significant effects of Cezanne on VSMC apoptosis,
NF-jB signalling, or inflammation. RNA-sequencing and biochemical studies showed that Cezanne drives VSMC
proliferation by regulating CCN family member 1 (CCN1) by targeting b-catenin for deubiquitination. Importantly,
local correction of Cezanne expression in the injured arteries greatly decreased VSMC proliferation, and prevented
arterial inward remodelling. Interestingly, global Cezanne gene deletion in mice led to smaller atherosclerotic pla-
ques, but with a lower level of plaque stability. Translating, we observed a similar role for Cezanne in human
VSMCs, and higher expression levels of Cezanne in human atherosclerotic lesions.
....................................................................................................................................................................................................
Conclusion Cezanne is a key regulator of VSMC proliferation and migration in pathological arterial remodelling. Our findings
have important implications for therapeutic targeting Cezanne signalling and VSMC pathology in vascular diseases.
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1. Introduction
Cardiovascular disease (CVD) is one of the leading causes for death
worldwide, and pathological arterial remodelling including neointimal
hyperplasia and atherosclerosis is a key determinant of these life-
threatening conditions. Therefore, understanding and controlling
pathological arterial remodelling is urgently required to manage patients
with CVDs. Vascular smooth muscle cell (VSMC) is the major cells in the
media layer of all the blood vessels, with critical roles in vasodilation and
vasoconstriction. In response to injury and inflammation, VSMCs
become activated and switch to a synthetic phenotype and contribute to
vascular remodelling or neointimal SMC hyperplasia.1 As such, dysfunc-
tional VSMCs have been implicated in many vascular diseases including
atherosclerosis,2–5 and fine-tuning regulation of VSMC function
represents a therapeutic possibility for post-angioplasty restenosis
and other CVDs.
Protein ubiquitination, and its reversal by protein de-ubiquitination
via deubiquitylating enzymes (DUBs), plays a critical role in governing
all essential cellular functions and controlling a variety of biological
processes.6,7 One of the DUBs, cellular zinc finger anti-NF-jB
(Cezanne) has been first cloned and characterized as a negative
regulator of the NF-jB signalling pathway by us in 2001.8 We were
the first to demonstrate that Cezanne is a novel DUB, which
can cleave ubiquitin monomers from ubiquitinated proteins.9
Subsequently, we have shown that Cezanne is induced by multiple
proinflammatory cytokines and, as an inhibitor of NF-jB
signal pathway, it forms a negative feedback loop in inflammatory
cytokine signalling.10,11Moreover, Cezanne can be induced by hypoxia
in endothelial cells through p38MAPK–dependent transcriptional and
post-transcriptional mechanisms, and by ischaemia in the murine kid-
ney, and Cezanne regulates inflammatory responses to hypoxia by
targeting tumour necrosis factor receptor–associated factor (TRAF) 6
for de-ubiquitination.12 Interestingly, a recent study from another
group revealed that Cezanne controls noncanonical NF-jB activation
through deubiquitination of TRAF3.13 Pathophysiologically, Cezanne
has been reported to regulate cancer progression14 and cell survival,15
and to be involved in the neuronal hyperplasia through modulating the
Notch signalling pathway.16 However, there is no report about the
functional involvements of Cezanne in VSMC pathology and arterial
remodelling in the literature. Here, we have provided clear
evidence that Cezanne is a key regulator of VSMC proliferation/
migration and arterial remodelling, and it regulates CCN1 expression
through controlling Wnt/b-catenin signalling pathway by targeting
b-catenin for deubiquitination.
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2.1 Animal experiments, anaesthesia, and
euthanasia
All animal experiments were conducted according to the Animals
(Scientific Procedures) Act of 1986 (United Kingdom). All the animal
procedures were approved by Queen Mary University of London
ethics review board (PPL number: PB508B78D), and conform to the
guidelines from Directive 2010/63/EU of the European Parliament on
the protection of animals used for scientific purposes or the NIH
guidelines (Guide for the care and use of laboratory animals).
For mouse femoral artery denudation injury and local gene transfer,
anaesthesia was induced using 100% O2/4% isoflurane, and was
maintained throughout the procedure by the administration of 100%
O2/2% isoflurane. At the end of protocol, all mice were euthanized
by placing them under deep anaesthesia with 100% O2/5% isoflurane,
followed by decapitation.
2.2 Mouse femoral artery denudation
injury and shRNA lentiviral particle
infusion
Eight-week-old male C57BL/6 mice were anaesthetized and the surgical
procedure was similar to that described previously.17–19 Briefly, the fem-
oral artery was dissected and injured by passing the tip (0.23mm) of an-
gioplasty spring-wire (Hi-Torque Winn 200T guide wire, Stock
Number: 1012474, Abbott Laboratories. Illinois, USA) for three to five
times. After endothelium denudation, the injured arteries were ran-
domly incubated with sh-NT or sh-Cez lentivirus. The procedures for lo-
cal SMC infection were similar to that described in our previous
studies20,21 with some modifications. In brief, immediately after injury,
10–20 mL of DMEM containing 1.0–2.0 106 sh-NT or sh-Cez lentiviral
particles was directly infused into the lumen of the injured femoral arter-
ies, followed by a 30-min incubation for local VSMC infection. As we pre-
viously reported with GFP lentivirus,21 local infusion of the lentivirus in
the injured arteries mainly results in SMC infection, with no or minimum
gene transduction in other aortic cells.
2.3 Analysis of human femoral and
coronary arteries
Human normal healthy and diseased femoral arteries were collected
and described in our previous study,17 and human coronary arterial
biopsy specimens22,23 were collected by Dr Robin Poston. Briefly, hu-
man arterial specimens were obtained from patients with peripheral
arterial diseases undergoing leg amputation at the First Affiliated
Hospital of Zhejiang University (China) between July 2014 and June
2017. All patients gave their written, informed consent prior to inclu-
sion in the study. All studies were approved by the Research Ethics
Committees of the First Affiliated Hospital of Zhejiang University
(2013/150), and all experiments were conducted according to the
principles expressed in the Declaration of Helsinki. It is worth noting
that the human coronary arterial autopsy specimens were harvested
with permission by Dr Robin Poston, a cardiovascular pathologist, in
the Department of Pathology, Guy’s Hospital, London (1980–1990).
The currently required study approval for collecting such specimens
was not applicable since the regulatory Human Tissue Act was not
enacted until 2004 in the UK. Standard immunofluorescence analysis
was conducted on paraffin sections of human femoral and coronary
arteries to examine respective protein expression as described in
Supplementary material online.
2.4 Statistical analysis
Results are presented as mean ± standard error of the mean (SEM).
Statistical analysis was performed using Graphpad Prism-8.3. Shapiro–
Wilk Normality Test was used for checking the normality of the data,
and all the data have passed the test. Two-tailed unpaired student’s t-test
was used for comparisons between two groups, or one-/two-way analy-
sis of variance with a post hoc test of Tukey’s analysis was applied when
more than two groups were compared. P<0.05 was considered statisti-
cally significant.
2.5 Additional materials and methods
Additional detailed description of materials and methods is provided in
Supplementary material online.
3. Results
3.1 Cezanne expression in VSMCs
As reported previously, Cezanne can be induced by hypoxia in endothe-
lial cells.12However, little is known about its expression and modulation
in VSMCs. We therefore first investigated if Cezanne expression could
be modulated by various atherogenic stimuli. Our data showed that
Cezanne was significantly up-regulated in VSMCs in response to 20%
foetal bovine serum (FBS), 10 ng/mL platelet-derived growth factor BB
(PDGF-BB), 50 ng/mL TNFa, and 1000ng/mL lipopolysaccharides (LPS)
treatments, while its expression level was not changed in response to
5 ng/mL transforming growth factor beta-1 (TGFb1) (Figure 1) stimula-
tion. As expected, we observed highest Cezanne expression in response
to both TNFa and LPS stimulation, which peaked at 6 h and reduced
thereafter. These data suggest that Cezanne plays a role in VSMC
responses to pathological factors.
3.2 Cezanne controls VSMC proliferation
and migration
To explore a role of Cezanne in various VSMC functions, VSMCs were
transfected with control (pHM6), wild-type (pHM6-Cez), or mutated
Cezanne (pHM6-Cez-C209S, Cys209 is a catalytic residue of Cezanne,
which is responsible for the deubiquitinating activity of Cezanne against
both linear and branched forms of polyubiquitin9) plasmid, and subjected
to various treatments and analyses as indicated. As expected, the expres-
sion of Cezanne was successfully up-regulated in VSMCs in the absence
or presence of various stimulations (Figure 2A and Supplementary mate-
rial online, Figure S1A). Importantly, Cezanne over-expression in VSMCs
significantly increased their proliferation under base level as well as in re-
sponse to both PDGF-BB and FBS stimulations, while such an increase
was almost abolished by over-expression of the mutated Cezanne
(pHM6-Cez-C209S) (Figure 2B and C). Similar effects were observed in
VSMC migration upon both PDGF-BB and FBS stimulations (Figure 2D
and Supplementary material online, Figure S1B). These data indicate that
Cezanne plays an important role in VSMC growth and mobility, and its
deubiquitinating activity is responsible for such effects. To further con-
firm the role of Cezanne in VSMC proliferation and migration, loss-of-
function experiments were conducted using Cezanne shRNA in VSMCs,
followed by similar treatments and assays. As shown in Figure 2E and
Supplementary material online, Figure S1E, the endogenous levels of





















































































































































Cezanne in VSMCs were significantly down-regulated by its shRNAs.
Consequently, VSMC proliferation (Figure 2F–G) and migration
(Figure 2H and Supplementary material online, Figure S1F) were signifi-
cantly inhibited once endogenous Cezanne was inhibited, further con-
firming a role for Cezanne in VSMC proliferation and migration.
3.3 Cezanne plays an insignificant role in
VSMC apoptosis, VSMC-specific gene
expression, NF-kB signalling, and
inflammatory response in VSMCs
Apart from proliferation and migration, VSMC apoptosis also play a role
in determining vascular pathological response after injury. We therefore
wondered if Cezanne could play a role in VSMC apoptosis. To this end,
similar Cezanne gain/loss-of-function experiments were conducted as
previously described. TUNEL staining assays showed that VSMC apo-
ptosis induced by combinational treatment with 100ng/mL TNFa and
200 ng/mL interferon gamma (IFN-c) was not impaired by either
Cezanne overexpression (Supplementary material online, Figure S1C and
D) or inhibition (Supplementary material online, Figure S1G and H).
Similarly, VSMC phenotype modulation is a well-known mechanism un-
derlying arterial remodelling upon injury. We thus examined if SMC-
specific gene expression were controlled by Cezanne. For this purpose,
VSMCs were transfected with Cezanne over-expression plasmids, and
subjected to TGFb1 treatment to induce SMC differentiation. Gene ex-
pression data (Supplementary material online, Figure S2) showed that
Cezanne was successfully up-regulated by both wild type and mutated
Cezanne plasmids in VSMCs. As expected, a variety of SMCmarker gene
expressions (SMaA, SM22a, h1-calponin, SMTN-B, and SM-myh11)
were significantly induced by TGFb1, while such gene inductions were
not impaired by Cezanne over-expression (Supplementary material on-
line, Figure S2), suggesting that Cezanne plays no role in TGFb1-induced
SMC gene expressions in VSMCs. Finally, VSMC inflammatory response
is another major determinant for neointimal SMC hyperplasia in re-
sponse to vascular injury, and functioning as NF-rB negative regulator
Cezanne has been recognized as one of major anti-inflammatory regula-
tors.We therefore speculated that Cezanne may play a role in VSMC in-
flammatory response. Surprisingly, although the NF-rB reporter activity
was hugely increased by both TNFa and Lps in VSMCs, their activity was
Figure 1 Cezanne expression is up-regulated in VSMCs treated with various atherogenic stimuli. Cultured VSMCs (p5–p8) were subjected to serum
starvation for 48h, followed by stimulation with 20% FBS, 10ng/mL PDGF-BB, 5 ng/mL TGFb1, 50 ng/mL TNFa, or 1000ng/mL Lps for the indicated
times. Total RNAs and protein (12 h) were harvested and subjected to RT-qPCR (A) and western blotting (B) analyses, respectively. The data presented
here are representative (left in B) or mean ± SEM of five independent experiments (n=5). *P<0.05, **<0.01, ***<0.001 (vs. 0 h or vehicle) (one-way
ANOVAwith a post hoc test of Tukey’s analysis).


























































































Figure 2 Cezanne regulates VSMC proliferation and migration. (A–D) Cezanne over-expression regulated VSMC functions. VSMCs transfected with
control (pHM6), wild-type (pHM6-Cez), or mutated (pHM6-C209S) Cezanne plasmids were subjected to serum starvation for 48h, followed by 10ng/
mL PDGF-BB, or 20% FBS stimulations for another 12 (migration) or 24 (proliferation) hours, respectively. (A) RT-qPCR analysis of Cezanne gene ex-
pression. (B and C) Cezanne over-expression promoted VSMC proliferation as demonstrated in total cell number count (B) and BrdU incorporation as-
say (C). (D) Cezanne increases VSMC migration as demonstrated in transwell migration assays. Note: no or only a few cells were migrated through the
inserts without a strong chemoattractant in the bottom chamber; therefore, no control treatment is shown in transwell migration assays. (E–H) Cezanne
gene knockdown in VSMCs. VSMCs infected with non-target (sh-NT) or Cezanne specific (sh-Cez) shRNA lentivirus were subjected to a similar treat-
ment and analysis as described in (A–D). The data presented here are mean ± SEM of six (n=6 in A–D and G–H) or eight (n=8 in E–F) independent
experiments. *P<0.05 (vs. pHM6 or sh-NT); #P<0.05 (pHM6-C209S vs. pHM6-Cez); &P<0.05 (vs. vehicle) (two-way ANOVA with a post hoc test of
Tukey’s analysis).













































































































































































































































































not impaired by Cezanne over-expression (Supplementary material on-
line, Figure S3A), suggesting that Cezanne plays no role in NF-rB signalling
activation in VSMCs. Such a notion was further supported by gene ex-
pression data (Supplementary material online, Figure S3B–H). Specifically,
while the gene expression levels of all the inflammatory genes (MCP-1,
iNOS, ICAM-1, VCAM-1, E-selectin, and IL6) examined in this study
were significantly up-regulated by both inflammatory stimuli, no apparent
effect of Cezanne over-expression on these gene expression was ob-
served (Supplementary material online, Figure S3C–H). Taken together,
above data have collectively demonstrated that Cezanne plays no signifi-
cant role in VSMC death, TGFb1-induced SMC gene expressions, and in-
flammatory response.
3.4 RNA sequencing analysis to uncover
the potential downstream targets of
cezanne and associated signal pathways in
VSMCs
In searching the potential downstream target genes of Cezanne in
VSMCs, total RNAs were extracted from VSMCs infected with control
and Cezanne knockdown shRNA lentivirus and subjected to RNA se-
quencing analyses. A total of 75 genes were significantly modulated by
Cezanne knockdown in VSMCs, with 18 up-regulated and 57 down-
regulated as shown in the Heatmap (Supplementary material online,
Figure S4A). Panther GO-Slim analysis showed that these modulated
genes could be categorized into seven GO-Slim molecular functions in-
cluding catalytic activity, binding, and transporter activity (Supplementary
material online, Figure S4B), fifteenGO-Slim biological processes (e.g. cel-
lular process, biological regulation, metabolic process, locomotion, and
growth) (Supplementary material online, Figure S4C), and 10 protein clas-
ses (e.g. metabolite interconversion enzyme, intercellular signal mole-
cule, protein modifying enzyme, extracellular matrix protein,
cytoskeletal protein, and nucleic acid binding protein) (Supplementary
material online, Figure S4D), respectively. The top enriched GO terms in
the three main domains of molecular function, biological process, and
protein class were shown in Supplementary material online, Figure S4E.
Among them, five GO terms were in the domain of molecular function,
which were mostly related to heparin/integrin binding, and cell adhesion
molecule binding; six GO terms were in the domain of biological pro-
cess, which were mainly related to regulation of cell migration, supramo-
lecular fibre organization, and cell death/adhesion; seven GO terms
were related to protein class, which were associated with growth factor,
extracellular matrix structural protein, extracellular matrix protein, and
general transcription factor.
3.5 Ccn1 is the top downstream target
gene modulated by Cezanne in VSMCs
Interestingly, as shown in the volcano plot analysis three CCN family
members including CCN1, CCN2 and CCN5 were down-regulated by
Cezanne inhibition (Figure 3A), which was further confirmed in RT-qPCR
analysis (Figure 3B). Importantly, Cezanne over-expression in VSMCs sig-
nificantly increased all three CCN genes expression, while such up-
regulations for CCN1 and CCN2, not for CCN5 gene was almost abol-
ished by over-expression of the mutated Cezanne (Figure 3C). In particu-
lar, CCN1 or cysteine-rich angiogenic inducer 61 (Cyr61), a secreted
and extracellular matrix-associated signalling protein of the CCN family,
has been signalled out as the most regulated gene by Cezanne in VSMCs
(Figure 3A–C). Moreover, CCN1 has a well-established role in VSMC pa-
thology and neointimal SMC hyperplasia upon vascular injury.24
Therefore, as a proof of concept we attempted to investigate how the
CCN1 gene expression being regulated by Cezanne in the context of
VSMC functions and neointimal formation. Data shown in Figure 3C sug-
gested that the deubiquitinating activity of Cezanne is critical for CCN1
gene regulation by Cezanne. To support such a mechanism, western
blotting analysis was conducted with total cell lysates and the immuno-
precipitated protein by a pan-ubiquitin antibody using anti-CCN1 anti-
body to examine total and ubiquitinated (modified) CCN1 protein,
respectively. We found that while the total CCN1 protein expression
level was significantly up-regulated by enforced expression of wild-type
but not the mutated version of Cezanne plasmids, the ubiquitinated
CCN1 protein was slightly down-regulated by Cezanne overexpression
(Figure 3D and E), suggesting that Cezanne-mediated protein deubiquiti-
nation may play a minor role in stabilizing CNN1 protein.
3.6 Cezanne regulates CCN1 through
activating b-catenin signalling
Previous studies have reported an important role for Wnt/b-catenin sig-
nalling in CCN1 gene regulation in cancer25 and mesenchymal stem
cells.26 To address if a similar mechanism is underlying the CCN1 gene
regulation in VSMCs, we firstly examined a possible effect of Cezanne on
Wnt/b-catenin signalling activity by conducting luciferase activity assays
with M50 Super (8x) TOPFlash reporter, and observed that the Wnt/b-
catenin signalling activity was expectedly induced by both FBS and
PDGF-BB treatments. Importantly, while Cezanne over-expression in
VSMCs significantly increased the reporter activity in the absence or
presence of the respective stimulations, such induction was blunted by
over-expression of the mutated Cezanne (Figure 4A), indicating that
Cezanne has a regulatory role for Wnt/b-catenin signalling in VSMCs,
and its deubiquitinating activity is responsible for such a role. Indeed, an
increased level of the total b-catenin, but a decreased level of ubiquiti-
nated b-catenin protein was observed in Cezanne over-expressing
VSMCs. Importantly, such regulatory effects were reversed by over-
expression of the mutated version of Cezanne (Figure 4B). These data
have collectively demonstrated that Cezanne up-regulates b-catenin sig-
nalling by targeting b-catenin protein for deubiquitination in VSMCs.
Moreover, co-transfection experiments were subsequently conducted
to examine if there is any potential link among Cezanne, b-catenin, and
CCN1 gene expression. Data shown in Figure 4C revealed that the b-cat-
enin gene expression level was not regulated by Cezanne overexpres-
sion in VSMCs, which was consistent with the RNA sequencing data
showing that b-catenin was not among the genes regulated by Cezanne
knockdown (Supplementary material online, Figure S4A). Importantly, we
found that while CCN1 gene expression was significantly down-
regulated and up-regulated by b-catenin inhibition and Cezanne over-
expression, respectively, CCN1 gene up-regulation by Cezanne was al-
most abrogated by b-catenin knockdown (Figure 4C), indicating that b-
catenin is required for Cezanne-mediated CCN1 gene regulation. To
further confirm the essence of b-catenin signalling in CCN1 gene regula-
tion by Cezanne, luciferase activity assays were conducted with a wild
type or WRE (Wnt-response element) mutated CCN1 gene promoter
reporter, respectively. We found that enforced expression of wild type,
but not the mutated Cezanne in VSMCs significantly up-regulated CCN1
gene promoter activity, while such regulation disappeared once the
WRE within CCN1 gene promoter was mutated (Figure 4D). Finally, data
from chromatin immunoprecipitation (ChIP) assay showed a significant
increased binding of b-catenin to CCN1 gene promoter upon Cezanne
over-expression, while such enhancement was almost abolished when


























































































Figure 3 Cezanne regulates CCN1 but not targets it for deubiquitination in VSMCs. (A) Volcano plot analysis showing three CCN genes modulated by
Cezanne knockdown in VSMCs. Total RNAs were isolated from VSMCs infected with non-target (sh-NT) or Cezanne specific (sh-Cez) shRNA lentivirus
and subjected to RNA-sequencing analysis, followed by Volcano plot analysis. (B) RT-qPCR analysis validated CCN genes expression. (C) CCN genes ex-
pression was regulated by Cezanne. (D–E) The expression level of total, but not the ubiquitinated CCN1 protein was regulated by Cezanne. VSMCs
transfected with control (pHM6), wild-type (pHM6-Cez) or mutated (pHM6-Cez-C209S) Cezanne plasmids were subjected to serum starvation for
48h, followed by 50ng/mL TNFa stimulations for another 6 h. After then, cells were treated with 20mM MG132 for 1 h. Pan-ubiquitin immunoprecipi-
tates or total cell lysates were tested by western blotting using anti-CCN1 antibody to examine ubiquitinated (modified CCN1) and total CCN1 protein,
respectively. The data presented here are representative (left panel inD) or mean ± S.E.M. of three (A, n=3) or six (B–E, n=6) independent experiments.
*P<0.05, **<0.01, ***<0.001 (vs. sh-NT or pHM6); #P<0.05, ##<0.01 (pHM6-Cez-C209S vs. pHM6-Cez) (B, unpaired t-test; C and E, one-way
ANOVAwith a post hoc test of Tukey’s analysis).


























































































Figure 4 Cezanne regulates CCN1 through activating b-catenin signalling. (A) Luciferase activity assays with M50 Super (8x) TOPFlash reporter showed
that b-catenin signal pathway was activated by Cezanne over-expression in VSMCs with different treatments. (B) Cezanne activates b-catenin signalling by
targeting it for deubiquitination in VSMCs. Following similar treatments as described in Figure 3D, pan-ubiquitin immunoprecipitates or total cell lysates were
prepared to examine ubiquitinated (modified b-catenin) and total b-catenin protein, respectively. (C) b-catenin is required for CCN1 gene regulation by
Cezanne. VSMCs were co-transfected with pHM6 or pHM6-Cez, and si-NT (non-target or scrambled siRNA) or si-Ctnnb1 (b-catenin specific siRNA) as















































































































































































































































overexpressed the mutated version of Cezanne plasmid in VSMCs
(Figure 4E). We therefore conclude that b-catenin signalling activation
and WRE within CCN1 gene promoter were essential for CCN1 gene
regulation by Cezanne.
3.7 Cezanne regulates VSMC proliferation
and migration through modulating CCN1
Co-transfection experiments were conducted to further address the
functional implication of CCN1 gene regulation by Cezanne in VSMC pa-
thologies. Gene expression data (Supplementary material online, Figure
S5A) showed that while CCN1 was successfully down-regulated and sig-
nificantly up-regulated by CCN1 specific siRNA and Cezanne overex-
pression plasmid, respectively, Cezanne expression was not affected by
CCN1 inhibition, suggesting that CCN1 is indeed the downstream gene
of Cezanne. Moreover, b-catenin gene expression was not impaired by
either Cezanne over-expression or CCN1 knockdown, further confirm-
ing that Cezanne regulates b-catenin at post-transcriptional level.
Consequently, we observed that VSMC proliferation was decreased by
CCN1 knockdown, but increased by Cezanne over-expression, while
the promotive effects of Cezanne over-expression on VSMC prolifera-
tion was blunted by CCN1 inhibition in the co-transfecting cells
(Supplementary material online, Figure S5B). A similar phenomenon was
found with VSMC migration (Supplementary material online, Figure S5C).
These data have collectively showed that CCN1 activation is required
for Cezanne-mediated VSMC growth and mobility.
3.8 Local Cezanne inhibition in the injured
arteries prevented VSMC proliferation and
reduced inward arterial remodelling
following injury
Immunostaining data showed that Cezanne was strongly expressed in
endothelium, but weakly expressed in SMC layer in normal murine aorta
(Supplementary material online, Figure S6). Moreover, we observed that
Cezanne gene and protein expressions were significantly up-regulated
upon injury, peaked at 14 days post-injury (Figure 5A–C), implying a role
for Cezanne in injury-induced arterial remodelling. To investigate the
in vivo functional relevance of Cezanne in arterial inward remodelling,
10–20mL of DMEM containing 1.0–2.0  106 lentiviral particles (sh-NT
or sh-Cez) was directly infused into the lumen of the injured femoral ar-
teries immediately after injury, followed by a 30-min incubation for local
VSMC infection. Aortic gene expression data showed that local direct in-
fusion of Cezanne specific (sh-Cez) lentivirus successfully down-
regulated Cezanne expression level in the injured vessels (Figure 5D). As
a result, both cell proliferation genes (PCNA and Ki67) were significantly
down-regulated in the injured arteries by sh-Cez (Figure 5D), and a simi-
lar trend was observed with both CCN1 and CCN2 gene (Figure 5E).
Interestingly, we found that local Cezanne inhibition increased two SMC
genes expressions in the injured arteries (Figure 5D). Moreover, we
observed no change for CCN5 gene expression in the injured arteries,
and dramatic increased expression levels of three inflammatory genes
(MCP-1, iNOS and IL6) in the injured vessels, but their expression was
not affected by Cezanne inhibition (Figure 5E). Consistently, less
Cezanne (Figure 5F and Supplementary material online, Figure S7), b-cate-
nin (Figure 5H and Supplementary material online, Figure S7) and CCN1
(Figure 5I and Supplementary material online, Figure S7) protein as well as
lower percentage of Ki67-positive cells (Figure 5G and Supplementary
material online, Figure S7) was observed within the media and neointima
layers of the injured vessels with Cezanne gene inhibition, confirming
that local Cezanne inhibition decreases VSMC proliferation after injury.
Importantly, the inward arterial remodelling upon injury was significantly
reduced by local restoration of the dysregulated Cezanne expression in
the injured arteries (Figure 5J and K).
3.9 Genetic deletion of Cezanne reduces
atherosclerotic lesion size but with
increased plaque vulnerability
Immunostaining analysis showed that Cezanne was expressed in vessel
wall of healthy aortic roots, albeit at a low level (Supplementary material
online, Figure S8). To further explore if Cezanne could play a role in ath-
erogenesis, we crossbred Cezanne transgenic gene-trapped (GT) mice
(CezGT/GT or Cez-/-) generated in our previous study12 with LDLR-/-
mice to generate Cezanne/LDLR double knockout mice (Cez-/-/LDLR-/-)
and their control littermates (Cezþ/þ/LDLR-/-). Eight-week-old male
mice were fed a high-fat diet to induce atherosclerosis as described in
our previous study.27 No Cezanne protein expression was detected in
atherosclerotic plaques of Cez-/-/LDLR-/- mice (Figure 6A), validating this
genetically modified model. Pathologically, Cez-/-/LDLR-/- mice had sub-
stantially less aortic atherosclerosis (>55% reduction compared with
controls, P<0.001) in aortic roots (Figure 6B and C). Importantly, com-
pared to control mice, much less collagen content (Figure 6D and E), and
a lower level of SMCs, but a higher level of macrophages (Figure 6F)
were observed in Cez-/-/LDLR-/- mice. These observations have collec-
tively confirmed a functional role for Cezanne in atherogenesis and pla-
que stabilization.
3.10 Increased expression of Cezanne in
human atherosclerosis
To translate our findings from mice to men, we first examined a possible
role of Cezanne in human aorta SMCs (hAoSMCs). Expectedly,
Cezanne over-expression in hAoSMCs (Supplementary material online,
Figure S9A) significantly increased their proliferation (Supplementary ma-
terial online, Figure S9B) and migration (Supplementary material online,
Figure S9C and D), while such increase was almost blunted by over-
expression of the mutated Cezanne, inferring a similar role for Cezanne
in human VSMC functions. Additionally, we demonstrated by RT-qPCR
that Cezanne expression is enhanced in human femoral arteries with
Figure 4 Continued
indicated. Total RNAs were collected and subjected to RT-qPCR analysis. (D) Wnt-response element (WRE) within CCN1 gene promoter is re-
quired for its gene regulation by Cezanne as demonstrated in luciferase activity assays with wild type (pGL3-CCN1) or WRE mutated (pGL3-
CCN1-WREmut) CCN1 gene promoter reporters. (E) CHIP assay showed that Cezanne promoted b-catenin binding to CCN1 gene promoter.
The data presented here are representative (upper panel in B) or mean ± SEM of five (n=5 in A, C–E) or six (n=6 in B) independent experiments.
*P<0.05, **<0.01, ***<0.001 (vs. pHM6 or pHM6/si-NT); #P<0.05, ##<0.01 (pHM6-Cez-C209S vs. pHM6-Cez, or pHM6-Cez/si-Ctnnb1 vs.
pHM6-Cez/si-NT); &P<0.05 (vs. vehicle) (one- (B–E) or two-way (A) ANOVAwith a post hoc test of Tukey’s analysis).


























































































Figure 5 Local restoration of the dysregulated Cezanne expression upon injury reduces neointima formation. (A–C) Up-regulated Cezanne expression in
response to vascular injury. Injured arterial segments were harvested from mice without (sham) or with injury at the indicated time points and subjected to
RT-qPCR (A) and western blot (B and C) analysis, respectively. The data presented in (A–C) are mean ± S.E.M. of five (A) or three (B and C) independent
experiments (Note: injured arterial segments from 3 or 5 mice were pooled as one independent biological sample in A or B/C, respectively). (D–E) Aortic
gene expression profiles determined by RT-qPCR analysis. After injury, 10–20 mL of DMEM containing 1.0–2.0  106 shRNA lentiviral particles (sh-NT or
sh-Cez) was directly infused into the lumen of the injured femoral arteries, followed by a 30-min incubation for local VSMC infection. At seven days (D–E),
14days (F–I), or 28days (J–K) post-treatment, injured arterial segments were harvested and subjected to RT-qPCR (D–E) and immunofluorescence staining
(F–I) analyses, respectively. The data presented in (D–E) are mean ± SEM. of five independent experiments (injured arterial segments from 3 mice were















































































































































































































































atherosclerotic lesion compared to those without lesion (Figure 7A).
Immunofluorescence staining (Figure 7B and C) showed a much higher
expression level of Cezanne protein in the diseased femoral arterial
specimens than that in healthy specimens. Finally, immunofluorescence
staining analysis of human coronary atherosclerotic plaques also con-
firmed a high expression level of Cezanne in coronary atherosclerosis
(Figure 7D). Importantly, a much higher Cezanne expression level was
observed in the plaque shoulder, compared with the adjacent regions re-
sembling normal healthy coronary artery (Figure 7D2 and D3). Taken to-
gether, these data demonstrate the potential involvement of Cezanne in
human atherogenesis.
4. Discussion
Vascular pathologies including atherosclerosis and arterial inward
remodelling upon vascular injury remain a challenging issue for treating
cardiovascular diseases. Deeper understanding into the aetiology and
pathogenesis of vascular pathologies may provide novel therapeutic
interventions for various vascular disorders. Here, we document a func-
tional role for Cezanne in modulating VSMC functions and injury-
induced vascular remodelling in vitro and in vivo. We first observed that
Cezanne expression was activated by a variety of atherogenic stimuli in
VSMCs.With cellular function aspects, we show that Cezanne has a pro-
found role in governing VSMC proliferation and migration, but has a neg-
ligible effect on VSMC apoptosis and inflammatory response.
Mechanistically, we found that the deubiquitinating activity of Cezanne is
critical for its functional effects on VSMC proliferation and migration.
Additionally, we have identified that CCN1 is the functional downstream
target of Cezanne in the context of VSMC functions and arterial remod-
elling. We also demonstrate that Cezanne regulates CCN1 expression
by activating Wnt/b-catenin signalling through targeting b-catenin pro-
tein for deubiquitination. Importantly, we translated our in vitro findings
to two murine models by demonstrating that vascular injury induced
neointima formation is inhibited by local inhibition and restoration of the
dysregulated Cezanne expression in injured arteries, and the atheroscle-
rotic lesion is reduced by genetic deletion of Cezanne in a hyperlipidemic
mice model. Finally but most importantly, we provide evidence to sup-
port the notion that Cezanne may play a role in human atherogenesis.
We have previously reported that Cezanne can be induced in multiple
immortalized cell lines (e.g. A549, Hela, and Hek293) by pro-
inflammatory stimuli TNFa/IL1,12,13 and in endothelial cells in response
to hypoxia-reoxygenation.12 In this study, we have shown that Cezanne
can also be induced in VSMCs by multiple atherogenic stimuli such as the
potent cellular mitogens PDGF-BB and high concentration of serum, and
pro-inflammatory stimuli TNFa and Lps. Interestingly, our previous study
has demonstrated that hypoxia-reoxygenation induced Cezanne expres-
sion in a p38-dependent manner in endothelial cells.12 It is plausible that
a similar mechanism underlies Cezanne expression induced by
abovementioned atherogenic stimuli in VSMCs since it has been exten-
sively reported that p38 mitogen-activated protein kinase signalling can
be activated by these stimuli in various cellular contexts including
VSMCs.
Cezanne controls cancer cell proliferation, survival, and migration,
and is recurrently up-regulated in numerous malignancies.14,28 In this
study, we report new cellular functions for Cezanne in regulating VSMC
proliferation and migration, and show that the deubiquitinating activity of
Cezanne is essential for its promotive effect on VSMC functions. No ap-
parent effects of Cezanne on VSMC apoptosis and TGFb1-induced
VSMC specific genes expression were observed (Supplementary mate-
rial online, Figure S2). However, we found that the expression levels of
two SMC genes (SMaA and Myh11) were up-regulated by local
Cezanne inhibition in the injured arteries (Figure 5D), suggesting a role
for Cezanne in SMC gene regulation or SMC differentiation in the con-
text of the injury-induced arterial remodelling. Such a discrepancy is
likely due to the fact that there are multiple cellular components in the
injured arteries could contribute to the total expression levels of these
two SMC genes. It has been widely reported that apart from the medial
VSMCs the neointimal SMC-like cells could also be derived from adven-
titial stem/progenitor cells,29,30 and/or trans-differentiated from either
adventitial fibroblasts31,32 or endothelial cells.33,34 Taken together, these
data suggest that VSMC functions are selectively regulated by Cezanne,
whereas the potential involvements of Cezanne in stem cell differentia-
tion and other cell trans-differentiation in the context of neointimal SMC
accumulation remain to be determined.
Opposite to its well-known role in NF-jB signalling and inflammatory
response as previously discussed, we surprisingly observed an insignifi-
cant role for Cezanne in regulation of VSMC inflammatory response
in vitro in response to pro-inflammatory cytokines (Supplementary mate-
rial online, Figure S3) and in vivo upon vascular injury (Figure 5E). These
unexpected observations suggest that Cezanne regulates NF-jB signal-
ling and inflammatory response in a cellular context- and/or disease-
dependent manner.
Apart from its involvement in cancers, Cezanne has also been impli-
cated in other pathological conditions. It has been reported that
Cezanne could inhibit renal inflammation and injury in murine kidneys
exposed to ischaemia followed by reperfusion via controlling NF-jB-de-
pendent inflammatory activation.12 Cezanne has also been found to reg-
ulate excessive endothelial cell proliferation and inflammation at
atheroprone regions of arteries via activating hypoxia-inducible factor
1a (HIF1a),35 probably also HIF2a.36 The later study suggests a role for
Cezanne in vascular diseases. This study is the first to report a pathologi-
cal role for Cezanne in these conditions. By utilising a well-established in-
jury-induced arterial remodelling model, we first demonstrate that local
inhibition of Cezanne in the injured arteries significantly prevents arterial
inward remodelling. Controlling cell proliferation, not the aortic inflam-
mation is the main contributing factor to the Cezanne-mediated arterial
inward remodelling upon injury, which is consistent with the in vitro
Figure 5 Continued
pooled for one independent experiment). Data presented in (F–I) are the quantitative data (mean ± SEM) of relative mean fluorescence intensity
(MFI) for Cezanne (F), b-catenin (H), and CCN1 (I) over DAPI, or the percentage of Ki67-positive cells (G) in the injured vessels from 6 mice (n=6
mice for each group). *P<0.05, **<0.01, ***<0.001 (vs. sham); #P<0.05 (sh-Cez vs. sh-NT). (J–K) HE staining analysis. Paraffin sections from both
groups (n=11 mice for sh-NT, and n=13 mice for sh-Cez) were prepared and subjected to H&E staining analyses. Representative images (J) and
morphological characteristics (K) including neointimal area, neointimal/media ratio, and media area at 28days post-injury were presented here.
**P<0.01 (sh-Cez vs. sh-NT) (C, Kruskal–Wallis test, A, D, E, one-way ANOVAwith a post hoc test of Tukey’s analysis; F–I and K, unpaired t-test).


























































































Figure 6 Genetic deletion of Cezanne reduces atherosclerotic lesion size as well as collagen and SMC content. Eight-week-old male Cezanne knock-
out mice (Cez-/-/LDLR-/-) and their littermates (Cezþ/þ/LDLR-/-) were fed an HFD for 12weeks. Aortic roots were harvested and subjected to various
analysis. (A) Cezanne expression in the atherosclerotic plaques. Representative images from six mice (n=6) were presented here. Note: white arrows in-
dicate SMaAþ cells co-express Cezanne within atherosclerotic lesion. (B–C) HE staining analysis showing Cezanne deficiency resulted in smaller athero-
sclerotic lesion. (D–E) Sirius Red staining analysis showed decreased collagen content within the atherosclerotic plaques of Cezanne knockout mice. (F)
Immunofluorescent staining showed a lower level of SMCs, but higher level of macrophages in Cezanne knockout mice. Data presented in (B–F) are rep-
resentative (B, D, and upper panel in F) and the quantitative data (mean ± S.E.M.) of atherosclerotic plaque area (C), collagen content (E), or staining area
for SMA and CD68 (bottom panel in F) from 10mice (n=10mice for each group) (C, E, and bottom panel in F, unpaired t-test).


























































































Figure 7 Increased Cezanne expression in the human atherosclerotic plaques. (A) RT-qPCR analysis of Cezanne expression in normal healthy (HFA)
and diseased human femoral arterial specimens (DFA, n=20). (B–C) Increased Cezanne protein levels in diseased femoral arteries as demonstrated in im-
munofluorescent staining analysis. Representative (B) and the quantitative data (mean ± S.E.M.) of relative mean fluorescence intensity (MFI, Cezanne
against DAPI) (C) from 10 patients (n=10 for each group) were presented here. (D) Cezanne detection in human coronary atherosclerotic plaques.
Paraffin sections from 10 coronary atherosclerotic plaques (n=10) were prepared and subjected to HE (D1) and immunofluorescent (D2 and D4) stain-
ing analysis, respectively. Representative (D1 and D2) and the quantitative data (mean ± S.E.M.) of relative mean fluorescence intensity (MFI, Cezanne
against DAPI) (D3) from plaque shoulder (PS) and adjacent regions (AR) were presented here. Note: arrows and arrowheads in D4 indicate SMaAþ/
Cezanneþ and SMaA-/Cezanneþ cells, respectively. A, C, and D3, unpaired t-test.













































































































































































































































































observation. Second murine model, feeding a high-fat diet to the male
LDLR-/- mice, was used to further examine the potential role for
Cezanne in atherogenesis. We found that atherogenesis in aortic roots
was decreased, but plaque vulnerability was increased in Cezanne knock-
out mice. Reduced SMC content within atherosclerotic plaques ob-
served in Cezanne knockout mice further confirmed a critical role for
Cezanne in VSMC proliferation as shown in arterial remodelling model
and in vitro VSMC functional studies. The clinical relevance of Cezanne in
vascular diseases was further confirmed in two distinct human athero-
sclerotic specimens collected in our previous studies,17,22,23 femoral ar-
teries isolated from amputated leg of patients with occluded peripheral
arterial diseases17 and coronary arterial biopsy specimens harvested
from patients who died of ischaemic coronary heart disease.22,23 We
therefore have collectively demonstrated that Cezanne has a regulatory
role in injury-induced arterial inward remodelling and hyperlipidaemia-
induced atherogenesis, supporting its therapeutic potential in various
vascular diseases including post-angioplasty restenosis and atherosclero-
sis. However, we should be cautious when considering any Cezanne-
modifying agent for treating atherosclerosis since Cezanne inhibition
could potentially increase plaque vulnerability to rupture, and therefore
further studies using plaque rupture models, in mice or large animals, are
warranted.
We have originally speculated that modulating VSMC inflammatory re-
sponse could be the key underlying mechanism of Cezanne-mediated
VSMC functions and arterial inward remodelling, but failed to confirm it
(Supplementary material online, Figure S3). Alternatively, we conducted
the unbiased RNA sequencing analysis to uncover the whole transcription
profile modulated by Cezanne. To avoid any potential artefactual effect of
the enforced expression of Cezanne in VSMCs on the transcription pro-
file, total RNAs isolated from VSMCs with Cezanne knockdown were
chosen for RNA sequencing analysis. We found a relative small number of
genes (75 genes) were modulated by inhibiting the endogenous Cezanne
expression level in VSMCs stimulated by TNFa. GO term enrichment
analysis revealed that Cezanne-mediated genes are mainly associated with
cellular and protein bindings (e.g. CCN1/Cyr61, CCN2/Ctgf, CCN5/
Wisp2, Ly96, and Shroom3), cellular protein modification process (e.g.
Inhbb, Loxl4, Ptpn12, Lox, Gpaa1, Usp50, and Zdhhc7), supramolecular fi-
bre and actin cytoskeleton organization (e.g. Limk1, Loxl4, Lox, Shroom3
and Amotl2) and cell migration/adhesion (e.g. Amotl2, Sema3f, CCN1/
Cyr61, CCN2/Ctgf, CCN5/Wisp2, and Fbln2), which further support our
observations that Cezanne specifically controls VSMC growth and mobil-
ity. Among the 58 genes down-regulated by Cezanne inhibition
(Supplementary material online, Figure S4A), the extracellular matrix-
associated signalling protein CCN1 caught our attention due to its
reported cellular functions in VSMC senescence,37 proliferation,38 migra-
tion,39 and adhesion,40 and its potential implications in neointima forma-
tion,24,38,41 arteriosclerotic intimal hyperplasia,42 as well as
atherosclerosis.43,44 All of these observations make CCN1 a perfect
downstream target of Cezanne signalling in the context of VSMC pathol-
ogy and vascular diseases. Indeed, as shown in Figure 3A. CNN1 is the
most significant down-regulating gene in response to Cezanne knock-
down in VSMCs. Functionally, we show that CCN1 gene activation is re-
quired for Cezanne-mediated VSMC functions since simultaneously over-
expressing Cezanne and knocking down CCN1 in VSMCs almost blunted
the promotive effects of Cezanne over-expression on VSMC proliferation
and migration (Supplementary material online, Figure S5).
However, how does Cezanne regulate CCN1 gene and protein ex-
pression in VSMCs? Previous studies have shown that Cezanne can di-
rect bind to ubiquitin,45 particularly the Lys63- and Lys11-linked
polyubiquitin chains,46–48 and remove those polyubiquitin chains from
signalling intermediaries to regulates distinct cellular functions.12,13 Our
data showed that the deubiquitinating activity of Cezanne is required for
both Cezanne-mediated CCN1 gene and protein up-regulation, indicat-
ing that Cezanne regulates CCN1 at transcriptional level, or via a tran-
scriptional mechanism. Indeed, immunoprecipitation assay using a pan-
ubiquitin antibody revealed that CCN1 protein ubiquitination was not
controlled by Cezanne. We therefore speculated there is another pro-
tein functioning as the signalling intermediary between Cezanne and
CCN1 regulation, such as b-catenin. The rationale behind the choosing
of b-catenin due to following facts: emerging evidence in the past decade
has not only established a critical role for Wnt/b-catenin signalling path-
way in embryogenesis and development, but also suggested that they
play a part in cardiovascular disorders through regulating VSMC prolifera-
tion, migration, and survival.49 Importantly, b-catenin has also been identi-
fied as the key regulator in vascular endothelium denudation-induced
neointima formation and progression in our previous studies.50,51 The re-
spective relevance and significance of Wnt/b-catenin signalling in VSMC
functions and vascular remodelling has been further delineated in vivo us-
ing an inducible, conditional genetic deletion of b-catenin in SMCs of adult
mice.52Although this pathway showed an undoubted role in VSMC phys-
iology and vascular diseases, our understanding of the underlying mecha-
nisms how this pathway to be regulated in vascular disorders, however,
remains incomplete. In this aspect, we have now established a mechanis-
tic link between Cezanne, Wnt/b-catenin signalling pathway, and CCN1
regulation in the context of VSMC functions and vascular diseases
(Figure 4). Specifically, we provide comprehensive evidence to show that
Cezanne can directly target b-catenin protein for deubiquitination, which
in turn stabilize b-catenin protein, activating Wnt/b-catenin signalling
pathway. Further data from co-transfection (Cezanne over-expression
and b-catenin knockdown) experiments, CCN1 gene promoter activity
assay, and CHIP assays confirmed the essence and necessity of b-catenin
and its DNA binding element WRE within CCN1 gene promoter in
CCN1 regulation by Cezanne.
One limitation in this study is that atherosclerosis was studied using
Cezanne knockout mice, whereas a well-established shRNA lentiviral
gene transfer technique was used to evaluate the possible functional role
of Cezanne in VSMC functions and injury-induced arterial remodelling.
This disparity was because we could not transfer knockout mice be-
tween institutes due to technical and regulatory issues. An additional lim-
itation is that Cezanne global knockout mice were used in this study,
therefore the observed effects of Cezanne on atherogenesis could also
attribute to any potential effects of Cezanne on other cells such as endo-
thelial cells and inflammatory cells, as evidenced by that Cezanne has
been previously demonstrated to play important roles in endothelial
cells,12 and it is highly expressed in endothelium (Supplementary material
online, Figure S6) as well as SMaA- cells within atherosclerotic plaques
(Figure 7D4). Despite these limitations, we have conclusively demon-
strated that Cezanne is a functional modulator for VSMC growth and
mobility, injury-triggered arterial inward remodelling, and
hyperlipidemia-induced atherogenesis. These functional and mechanistic
observations could open a new avenue to further explore their thera-
peutic potential for treating post-angioplasty restenosis and atheroscle-
rosis by targeting Cezanne/b-catenin/CCN1 signalling axis.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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Schieffer B, Drexler H. Expression of CYR61, an angiogenic immediate early gene, in
arteriosclerosis and its regulation by angiotensin II. Circulation 2002;106:254–260.
45. Mader J, Huber J, Bonn F, Dotsch V, Rogov VV, Bremm A. Oxygen-dependent aspar-
agine hydroxylation of the ubiquitin-associated (UBA) domain in Cezanne regulates
ubiquitin binding. J Biol Chem 2020;295:2160–2174.
46. Mevissen TET, Kulathu Y, Mulder MPC, Geurink PP, Maslen SL, Gersch M, Elliott PR,
Burke JE, van Tol BDM, Akutsu M, Oualid FE, Kawasaki M, Freund SMV, Ovaa H,
Komander D. Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase
Cezanne. Nature 2016;538:402–405.
47. Bremm A, Freund SM, Komander D. Lys11-linked ubiquitin chains adopt compact
conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne. Nat
Struct Mol Biol 2010;17:939–947.
48. Wu X, Liu S, Sagum C, Chen J, Singh R, Chaturvedi A, Horton JR, Kashyap TR,
Fushman D, Cheng X, Bedford MT, Wang B. Crosstalk between Lys63- and Lys11-
polyubiquitin signaling at DNA damage sites is driven by Cezanne. Genes Dev 2019;
33:1702–1717.
49. Mill C, George SJ. Wnt signalling in smooth muscle cells and its role in cardiovascular
disorders. Cardiovasc Res 2012;95:233–240.
50. Xiao Q, Zhang F, Grassia G, Hu Y, Zhang Z, Xing Q, Yin X, Maddaluno M, Drung B,
Schmidt B, Maffia P, Ialenti A, Mayr M, Xu Q, Ye S. Matrix metalloproteinase-8 pro-
motes vascular smooth muscle cell proliferation and neointima formation. Arterioscler
Thromb Vasc Biol 2014;34:90–98.
51. Zhou B, Margariti A, Zeng L, Habi O, Xiao Q, Martin D, Wang G, Hu Y, Wang X,
Xu Q. Splicing of histone deacetylase 7 modulates smooth muscle cell proliferation
and neointima formation through nuclear beta-catenin translocation. Arterioscler
Thromb Vasc Biol 2011;31:2676–2684.
52. Riascos-Bernal DF, Chinnasamy P, Gross JN, Almonte V, Egana-Gorrono L, Parikh D,
Jayakumar S, Guo L, Sibinga NES. Inhibition of smooth muscle beta-catenin hinders
neointima formation after vascular injury. Arterioscler Thromb Vasc Biol 2017;37:
879–888.
Translational Perspective
In this study, we have identified the deubiquitinating enzyme Cezanne as a novel regulator in governing VSMC phenotype, injury-induced neointimal
hyperplasia, and hyperlipidaemia-induced atherosclerosis. Since accumulating evidence highlights an important role for VSMC dysfunctions in many
cardiovascular pathological conditions including atherosclerosis, arterial remodelling, hypertension, and stroke, local modulation of this newly identi-
fied signal axis (Cezanne/b-catenin/CCN1) could represent as a novel therapy for post-angioplasty restenosis and aforementioned diseases.
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